Interstitial lung diseases (ILDs) represent a broad group of heterogeneous parenchymal lung diseases. Some ILDs progress, causing architectural distortion and pulmonary fibrosis, and thus are called fibrotic ILDs. Recent studies have shown a beneficial effect of antifibrotic therapy in fibrotic ILDs other than idiopathic pulmonary fibrosis (IPF) that manifest progressive pulmonary fibrosis (PPF). However, it remains challenging to predict which patients with fibrotic ILDs will demonstrate PPF. Precision medicine approaches could identify patients at risk for progression and guide treatment in patients with IPF or PPF.

中文翻译：

---

纤维化间质性肺病精准医学的曙光


间质性肺疾病 （ILD） 代表了一大类异质性肺实质疾病。一些 ILD 进展，导致结构扭曲和肺纤维化，因此被称为纤维化 ILD。最近的研究表明，抗纤维化治疗对表现为进行性肺纤维化 （PPF） 的特发性肺纤维化 （IPF） 以外的纤维化 ILD 具有有益效果。然而，预测哪些纤维化 ILD 患者会出现 PPF 仍然具有挑战性。精准医学方法可以识别有进展风险的患者，并指导 IPF 或 PPF 患者的治疗。